Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
462 Research products, page 1 of 47

  • COVID-19
  • Publications
  • Research data
  • Other research products
  • Open Access
  • Other ORP type
  • ZENODO

10
arrow_drop_down
Relevance
arrow_drop_down
  • Open Access
    Authors: 
    Setayesh Yazdani; Nicola De Maio; Matthieu Schapira;
    Publisher: Zenodo

    This document is about the druggability and genetic variability of the ADP-bound pocket of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) NiRAN domain across coronaviruses and SARS-CoV-2 samples. This report also accompanies this post on https://openlabnotebooks.org/.

  • Open Access
    Authors: 
    Lin Chen;
    Publisher: Zenodo

    This repository contains the code used in our paper: Strategic COVID-19 vaccine distribution can simultaneously elevate social utility and equity.

  • Other research product . Other ORP type . 2021
    Open Access
    Authors: 
    Isensee, Fabian;
    Publisher: Zenodo

    COVID-19-20 submission (second place on test set). See the nnU-Net repository for information on how to use the weights (Link) Challenge Website: https://covid-segmentation.grand-challenge.org/ Leaderboard: https://covid-segmentation.grand-challenge.org/Final-Ranking/

  • Open Access English
    Authors: 
    Hayder Fawzi; Haydar Al-Tukmagi;
    Publisher: Zenodo

    examination of pharmacy students

  • Open Access
    Authors: 
    Matthew Koster1;
    Publisher: Zenodo

    Background: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and JAK1. However, JAK inhibition in patients with GCA has not been formerly investigated. Methods: We performed a prospective, open-label, pilot study of baricitinib (4mg/day) in patients with relapsing GCA. The primary outcome was the frequency of adverse events and serious adverse events at week 52. Secondary outcomes included relapse at week 24 and week 52, change in pre-enrollment erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) to week 24 and week 52, and comparison of glucocorticoid dose at enrollment to week 24 and week 52. The study schema is outlined in Figure 1. Results: 15 patients were enrolled in the study (11, 73% female) with a mean(SD) age at entry 72.4(7.2) years, median(IQR) duration of GCA of 9 (7, 21) months, and median of 1 (1, 2) prior relapse. Treatments prior to study entry included: glucocorticoids (15, 100%); methotrexate (2, 13%); cyclophosphamide (1, 7%); sirukumab (1, 7%). Characteristics at GCA diagnosis and at relapse prior to study entry are listed in Table 1. Four (27%) patients entered the study on prednisone 30mg/day, 6 (40%) at 20 mg/day, and 5 (33%) at 10mg/day. One patient with baseline chronic kidney disease had a decline in renal function below study threshold for continuation and was withdrawn at week 8. The remaining 14 patients completed 52 weeks of baricitinib. At week 52, 14/15 (93%) patients had at least one adverse event recorded with the most frequent events including: infection not requiring antibiotics (n=8), infection requiring antibiotics (n=5), nausea (n=6), leg swelling (n=2), fatigue (n=2), diarrhea (n=1), abdominal pain (n=1). Two patients contracted COVID-19 during the study, both with mild symptoms, neither hospitalized. One patient had a serious adverse event during the study (transient thrombocytopenia attributed to concomitant use of antimicrobial therapy). Study outcomes are listed in Table 2. ESR and CRP were significantly lower at week 24 and week 52 compared to pre-enrollment values. Patient global assessment at week 0 was also significantly improved at both week 24 and week 52. Only 1 of 14 (7%) patients relapsed during the study (same patient at week 24 and week 52). The remaining 13 patients achieved steroid discontinuation and remained in disease remission during the duration of the 52-week study. Among patients completing the study, 4/14 (29%) flared during the 12-week follow up period after baricitinib discontinuation. Conclusion: In this proof of concept study, baricitinib at a dose of 4mg/day appeared both safe and effective in the management of patients with relapsing GCA. Larger randomized clinical trials are needed to determine the utility of JAK inhibition in GCA. Disclosures: KW received funds from Eli Lilly and Company to assist in the completion of the clinical trial. MK, CS, RG, JJ, EM, AD-G, CW report no financial disclosures of interest related to this study.

  • Open Access English
    Authors: 
    Serkan Sayıner; Ahmet Özer Şehirli;
    Publisher: Zenodo

    Although the types of coronaviruses seen in animals differ, recent studies have also shown that they are affected by COVID-19, known as SARS-CoV-2. The impact of COVID-19 on animals is a factor that should be followed carefully, especially since different variants appear in humans every day and this disease is transmitted from human to animal. Thanks to vaccination, animals are less affected by different types of coronaviruses. Cats and ferrets are especially affected much more in COVID-19, causing damage to the lungs and other organs. Recently, it has been shown that the use of monoclonal antibodies, especially in the early stages of COVID-19, by people with chronic diseases, positively affects the course of the disease, reduces the frequency of hospitalization and the possibility of falling into intensive care. Sotrovimab is a pan-sarbecovirus monoclonal antibody, and 12-13 studies to date have shown that individuals with chronic disease are less affected when given in the early stages of the disease when the symptoms are mild. We also think that if especially old cats and ferrets are treated with Sotrovimab in the early stages of the disease when they contract COVID-19, it will positively affect the prognosis of the disease.

  • Open Access Spanish
    Authors: 
    MENDOZA SALINAS BRENDA KAREN;
    Publisher: Zenodo

    El espectro clínico de la infección por Dengue y el COVID-19 presenta gran similitud en relación a los eventos fisiopatológicos. Por ello el presente trabajo tiene por finalidad conocer las características clínicas y de laboratorio en pacientes pediátricos con coinfección por dengue y COVID-19, Hospital EsSalud III – Iquitos, 2020. Se realizó un estudio de tipo descriptivo en 57 pacientes atendidos. Concluyendo que los síntomas más frecuentes fueron la fiebre (100 %), cefalea (70,2 %), astenia (68,4 %), náuseas (66,7 %) y vómitos (64,9 %). En menor proporción se observa que los pacientes presentaron escalofríos (52,6 %) y dolor abdominal (42,1 %). La pérdida de olfato y de gusto presentaron menor frecuencia. El 64,9 % presentaron leucocitos < 4000 / mm3, mientras que solo el 1,8 % presentaron leucocitos > 10 000 / mm3. Respecto a los linfocitos se observa que el 64,9 % presentaron linfocitos < 1500 / mm3 y 1,8 % presentaron linfocitos > 4000 / mm3. Respecto a neutrófilos se observa que 64,9 % de pacientes presentaron neutrófilos < 2000 / mm3. El 29,8 % presentaron eosinófilos < 40 / mm3 y el resto valores de 40 a 500 / mm3. En cuanto a monocitos el 21 % presentó un valor < 200 / mm3, el 3,5 % presentaron un valor > 800 / mm3. El 17,5 % de los pacientes presentaron basófilos < 10 / mm3, el 63,2 % 10 a 100 / mm3 y el 19,3 % > 100 / mm3. Respecto al hematocrito, se observa que el 71,9 % de pacientes presentaron hematocrito de 35 a 48 % y el 28,1 % un hematocrito menor a 35 %, el 41 % presentaron hemoglobina <12 g/dL y solo el 10,3 % un valor > 14 g/dL. La mayoría de pacientes presentaron plaquetas < 150000 / mm3. Palabras clave: COVID-19, dengue

  • Open Access
    Authors: 
    J. E. Pekar; J. O. Wertheim;
    Publisher: Zenodo

    Data 5 for the manuscript. Refer to Data 1 for the full description and links to the remaining datasets: https://doi.org/10.5281/zenodo.6887186

  • Open Access French
    Authors: 
    GEBEIL Sophie; FELIX Christine; FILIPPI Pierre-Alain; MARTIN Perrine;
    Publisher: Zenodo

    Le questionnaire a été diffusé en ligne du 9 avril 2020 au 7 juin 2020 sur http://sphinx2.espe.univ-amu.fr/v4/s/9ab5go Il a recueilli 4071 réponses.

  • Open Access French
    Authors: 
    cecile Touitou;
    Publisher: Zenodo

    Synthèse des commentaires de l'Enquête sur les usages documentaires pendant l'année 2020 (Covid19) des usagers de la bibliothèque de Sciences Po

Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
462 Research products, page 1 of 47
  • Open Access
    Authors: 
    Setayesh Yazdani; Nicola De Maio; Matthieu Schapira;
    Publisher: Zenodo

    This document is about the druggability and genetic variability of the ADP-bound pocket of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) NiRAN domain across coronaviruses and SARS-CoV-2 samples. This report also accompanies this post on https://openlabnotebooks.org/.

  • Open Access
    Authors: 
    Lin Chen;
    Publisher: Zenodo

    This repository contains the code used in our paper: Strategic COVID-19 vaccine distribution can simultaneously elevate social utility and equity.

  • Other research product . Other ORP type . 2021
    Open Access
    Authors: 
    Isensee, Fabian;
    Publisher: Zenodo

    COVID-19-20 submission (second place on test set). See the nnU-Net repository for information on how to use the weights (Link) Challenge Website: https://covid-segmentation.grand-challenge.org/ Leaderboard: https://covid-segmentation.grand-challenge.org/Final-Ranking/

  • Open Access English
    Authors: 
    Hayder Fawzi; Haydar Al-Tukmagi;
    Publisher: Zenodo

    examination of pharmacy students

  • Open Access
    Authors: 
    Matthew Koster1;
    Publisher: Zenodo

    Background: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and JAK1. However, JAK inhibition in patients with GCA has not been formerly investigated. Methods: We performed a prospective, open-label, pilot study of baricitinib (4mg/day) in patients with relapsing GCA. The primary outcome was the frequency of adverse events and serious adverse events at week 52. Secondary outcomes included relapse at week 24 and week 52, change in pre-enrollment erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) to week 24 and week 52, and comparison of glucocorticoid dose at enrollment to week 24 and week 52. The study schema is outlined in Figure 1. Results: 15 patients were enrolled in the study (11, 73% female) with a mean(SD) age at entry 72.4(7.2) years, median(IQR) duration of GCA of 9 (7, 21) months, and median of 1 (1, 2) prior relapse. Treatments prior to study entry included: glucocorticoids (15, 100%); methotrexate (2, 13%); cyclophosphamide (1, 7%); sirukumab (1, 7%). Characteristics at GCA diagnosis and at relapse prior to study entry are listed in Table 1. Four (27%) patients entered the study on prednisone 30mg/day, 6 (40%) at 20 mg/day, and 5 (33%) at 10mg/day. One patient with baseline chronic kidney disease had a decline in renal function below study threshold for continuation and was withdrawn at week 8. The remaining 14 patients completed 52 weeks of baricitinib. At week 52, 14/15 (93%) patients had at least one adverse event recorded with the most frequent events including: infection not requiring antibiotics (n=8), infection requiring antibiotics (n=5), nausea (n=6), leg swelling (n=2), fatigue (n=2), diarrhea (n=1), abdominal pain (n=1). Two patients contracted COVID-19 during the study, both with mild symptoms, neither hospitalized. One patient had a serious adverse event during the study (transient thrombocytopenia attributed to concomitant use of antimicrobial therapy). Study outcomes are listed in Table 2. ESR and CRP were significantly lower at week 24 and week 52 compared to pre-enrollment values. Patient global assessment at week 0 was also significantly improved at both week 24 and week 52. Only 1 of 14 (7%) patients relapsed during the study (same patient at week 24 and week 52). The remaining 13 patients achieved steroid discontinuation and remained in disease remission during the duration of the 52-week study. Among patients completing the study, 4/14 (29%) flared during the 12-week follow up period after baricitinib discontinuation. Conclusion: In this proof of concept study, baricitinib at a dose of 4mg/day appeared both safe and effective in the management of patients with relapsing GCA. Larger randomized clinical trials are needed to determine the utility of JAK inhibition in GCA. Disclosures: KW received funds from Eli Lilly and Company to assist in the completion of the clinical trial. MK, CS, RG, JJ, EM, AD-G, CW report no financial disclosures of interest related to this study.

  • Open Access English
    Authors: 
    Serkan Sayıner; Ahmet Özer Şehirli;
    Publisher: Zenodo

    Although the types of coronaviruses seen in animals differ, recent studies have also shown that they are affected by COVID-19, known as SARS-CoV-2. The impact of COVID-19 on animals is a factor that should be followed carefully, especially since different variants appear in humans every day and this disease is transmitted from human to animal. Thanks to vaccination, animals are less affected by different types of coronaviruses. Cats and ferrets are especially affected much more in COVID-19, causing damage to the lungs and other organs. Recently, it has been shown that the use of monoclonal antibodies, especially in the early stages of COVID-19, by people with chronic diseases, positively affects the course of the disease, reduces the frequency of hospitalization and the possibility of falling into intensive care. Sotrovimab is a pan-sarbecovirus monoclonal antibody, and 12-13 studies to date have shown that individuals with chronic disease are less affected when given in the early stages of the disease when the symptoms are mild. We also think that if especially old cats and ferrets are treated with Sotrovimab in the early stages of the disease when they contract COVID-19, it will positively affect the prognosis of the disease.

  • Open Access Spanish
    Authors: 
    MENDOZA SALINAS BRENDA KAREN;
    Publisher: Zenodo

    El espectro clínico de la infección por Dengue y el COVID-19 presenta gran similitud en relación a los eventos fisiopatológicos. Por ello el presente trabajo tiene por finalidad conocer las características clínicas y de laboratorio en pacientes pediátricos con coinfección por dengue y COVID-19, Hospital EsSalud III – Iquitos, 2020. Se realizó un estudio de tipo descriptivo en 57 pacientes atendidos. Concluyendo que los síntomas más frecuentes fueron la fiebre (100 %), cefalea (70,2 %), astenia (68,4 %), náuseas (66,7 %) y vómitos (64,9 %). En menor proporción se observa que los pacientes presentaron escalofríos (52,6 %) y dolor abdominal (42,1 %). La pérdida de olfato y de gusto presentaron menor frecuencia. El 64,9 % presentaron leucocitos < 4000 / mm3, mientras que solo el 1,8 % presentaron leucocitos > 10 000 / mm3. Respecto a los linfocitos se observa que el 64,9 % presentaron linfocitos < 1500 / mm3 y 1,8 % presentaron linfocitos > 4000 / mm3. Respecto a neutrófilos se observa que 64,9 % de pacientes presentaron neutrófilos < 2000 / mm3. El 29,8 % presentaron eosinófilos < 40 / mm3 y el resto valores de 40 a 500 / mm3. En cuanto a monocitos el 21 % presentó un valor < 200 / mm3, el 3,5 % presentaron un valor > 800 / mm3. El 17,5 % de los pacientes presentaron basófilos < 10 / mm3, el 63,2 % 10 a 100 / mm3 y el 19,3 % > 100 / mm3. Respecto al hematocrito, se observa que el 71,9 % de pacientes presentaron hematocrito de 35 a 48 % y el 28,1 % un hematocrito menor a 35 %, el 41 % presentaron hemoglobina <12 g/dL y solo el 10,3 % un valor > 14 g/dL. La mayoría de pacientes presentaron plaquetas < 150000 / mm3. Palabras clave: COVID-19, dengue

  • Open Access
    Authors: 
    J. E. Pekar; J. O. Wertheim;
    Publisher: Zenodo

    Data 5 for the manuscript. Refer to Data 1 for the full description and links to the remaining datasets: https://doi.org/10.5281/zenodo.6887186

  • Open Access French
    Authors: 
    GEBEIL Sophie; FELIX Christine; FILIPPI Pierre-Alain; MARTIN Perrine;
    Publisher: Zenodo

    Le questionnaire a été diffusé en ligne du 9 avril 2020 au 7 juin 2020 sur http://sphinx2.espe.univ-amu.fr/v4/s/9ab5go Il a recueilli 4071 réponses.

  • Open Access French
    Authors: 
    cecile Touitou;
    Publisher: Zenodo

    Synthèse des commentaires de l'Enquête sur les usages documentaires pendant l'année 2020 (Covid19) des usagers de la bibliothèque de Sciences Po